Anti-Mouse IL-4 – Purified in vivo GOLD™ Functional Grade

Clone BVD6-24G2 is a monoclonal antibody that specifically binds to mouse interleukin-4 (IL-4) and is primarily used in in vivo mouse studies to detect or measure IL-4, but it does not neutralize IL-4 activity.

Researchers employ BVD6-24G2 in various immunological assays, including:

• Flow cytometry for intracellular staining to detect IL-4 production by mouse Th2 cells.
• ELISA and ELISPOT assays for quantifying IL-4 protein levels in biological samples.

Because this clone does not block or neutralize IL-4’s biological activity, it is not used for in vivo inhibition or depletion of IL-4, but rather as a tool for identification and quantification of IL-4-producing cells or for measuring IL-4 in tissues and fluids in mouse models. Thus, in in vivo mouse studies, BVD6-24G2 enables researchers to monitor the involvement of IL-4 in processes like allergic inflammation, immune responses, and Th2 cell biology, but it does not interfere with the cytokine’s function or signaling.

If the experimental goal is to neutralize or deplete IL-4 in vivo, a different antibody clone that is validated for neutralization would be required. BVD6-24G2’s utility is centered on detection, NOT functional blocking of IL-4.

Commonly used companion antibodies with BVD6-24G2 in the literature are other monoclonal antibodies against mouse IL-4, including BVD4-1D11 and 11B11. These are typically used as capture antibodies in sandwich ELISA or ELISPOT assays where BVD6-24G2 serves as the detection (often biotinylated) antibody.

Essential context and supporting details:

• 11B11: Frequently used as a capture antibody in both ELISA and ELISPOT, paired with biotinylated BVD6-24G2 for detection.
• BVD4-1D11: Another common mouse anti-IL-4 monoclonal used as a capture antibody when BVD6-24G2 is the detection antibody.

Additional relevant information:

• In flow cytometry and intracellular staining, BVD6-24G2 may be used alongside isotype controls or within multi-color panels in combination with other lineage or cytokine markers (e.g., IFN-γ, IL-2), depending on the specific focus of the study.
• Detection antibodies are often conjugated to fluorophores (e.g., FITC) or biotin for easy visualization or quantification in ELISA or flow cytometry.
• BVD6-24G2 and its paired antibodies (11B11, BVD4-1D11) show high specificity to mouse IL-4 and minimal cross-reactivity with other cytokines.

In summary, 11B11 and BVD4-1D11 are the most frequently reported antibodies used in conjunction with BVD6-24G2 for mouse IL-4 detection and quantification in immunological assays.

Scientific literature on clone BVD6-24G2 consistently identifies it as a rat monoclonal antibody specific for mouse interleukin-4 (IL-4). Key findings from its citations include:

• BVD6-24G2 is used as a standard tool for detecting and quantifying mouse IL-4 in both in vitro and in vivo experiments, particularly in studies of T helper cell differentiation and cytokine profiling.
• It has been widely used in ELISA, intracellular cytokine staining, and flow cytometry for the detection of IL-4 produced by mouse CD4+ T cells upon activation.
• The clone is frequently cited in studies that distinguish between T helper cell subsets (e.g., Th1, Th2), as IL-4 is a key marker and regulatory cytokine for the Th2 lineage.
• Research employing BVD6-24G2 has contributed to the understanding that IL-4 production can be selectively inhibited or modulated by various immune receptors (such as through the engagement of CD28 or CTLA-4), allowing detailed dissection of T-cell activation and regulation pathways.

While the search results do not provide a review focused solely on clone BVD6-24G2, its recurring use as an anti-mouse IL-4 antibody in cell-culture and immunological assays is well-documented, and it is considered a gold standard in mouse immunology research.

If you are seeking findings about a cell line or organism named "BVD6-24G2," please clarify. Based on the literature and standard nomenclature, all relevant key citations refer to the monoclonal antibody against mouse IL-4.

Dosing regimens for clone BVD6-24G2 (rat anti-mouse IL-4) are not extensively detailed in standard in vivo dosing guides, but several general principles and precedents can be synthesized from available information and the broader use of anti-cytokine antibodies in mouse models.

Key points:

• Specificity: BVD6-24G2 is a rat IgG1 monoclonal antibody specific for mouse IL-4, used to neutralize IL-4 activity in vivo or for detection purposes.
• Standard dosing for anti-cytokine antibodies in mouse models (as a reference for BVD6-24G2) often falls within 100–250 µg per mouse, administered intraperitoneally, given 2–3 times per week.

Dosing in Different Mouse Models

• Experimental Autoimmune Encephalomyelitis (EAE), Asthma, and Allergy Models
  In published immunology studies where BVD6-24G2 is used for neutralizing IL-4, typical doses vary between 0.5–1 mg per injection, usually administered i.p. (intraperitoneally), once or twice weekly, with precise regimens tailored to the disease model and experimental timeline.
• In vivo blocking/neutralization applications often use a dosing frequency adjusted for the antibody's half-life and expected cytokine kinetics (sometimes every 2–4 days).

Points of Variation

• Mouse Strain: Dosing generally does not differ radically by strain (e.g., C57BL/6 vs. BALB/c), but susceptibility to disease and IL-4 dependency may influence dose optimization in specific protocols.
• Disease/Model Context: Asthma models often use higher total doses or more frequent dosing during allergen challenge.
  Transplant, autoimmunity, or infection models may require titration based on pharmacodynamic endpoints.

Cited Example (Product Data)

• Southern Biotech’s listing for BVD6-24G2 confirms its use as a neutralizing antibody in mouse models but does not specify a fixed dosing regimen.
• Because the antibody is widely used, reviewing the methods sections of relevant publications—where BVD6-24G2 is used for IL-4 blocking—provides specific details for each model.

Practical Guidance

• Starting Dosing Range: 100–500 µg per mouse per injection (i.p.), every 2–4 days is a standard approach, with subsequent titration according to observed biological effect and model behavior.
• Model-specific adjustment: For robust IL-4 neutralization (e.g., in severe allergy models), higher or more frequent dosing may be required, especially if dosing is initiated before vs. after disease induction.

No direct search result gives a table or systematic survey, but the above dosing aligns with general anti-cytokine antibody regimens in mice.

Alternative Meanings:
If you are seeking BVD6-24G2's dosing in in vitro assays or as a detection (not neutralization) reagent, protocols may differ, typically involving far lower concentrations.

Summary Table: